Chronic transfusion practice for children with sickle cell anaemia and stroke

Chronic transfusions to maintain haemoglobin S (HbS) ≤30% are the mainstay of treatment for children with sickle cell anaemia (SCA) and previous stroke. This HbS target is often hard to maintain, however, and values achieved in current practice are unknown. In preparation for the Phase III Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial, we collected data on 295 children with SCA and stroke who received transfusions at 23 institutions. The overall average pre‐transfusion %HbS was 35 ± 11% (institutional range 22–51%). Receiving scheduled transfusions on time was the most predictive variable for maintaining HbS at the ≤30% goal.

[1]  R. Ware,et al.  Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. , 2004, The Journal of pediatrics.

[2]  C. Pegelow,et al.  Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. , 2002, The Journal of pediatrics.

[3]  Scott T. Miller,et al.  Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. , 1995, The Journal of pediatrics.

[4]  J. Silber,et al.  A modified transfusion program for prevention of stroke in sickle cell disease. , 1992, Blood.

[5]  J. Morris,et al.  Stroke in a cohort of patients with homozygous sickle cell disease. , 1992, The Journal of pediatrics.

[6]  K. Ohene‐Frempong.  Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. , 1991, Seminars in hematology.

[7]  R. Mulhern,et al.  High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. , 1991, The Journal of pediatrics.

[8]  F. Moll,et al.  HIGH RISK , 1990, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[9]  J. Langston,et al.  Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. , 1980, The Journal of pediatrics.

[10]  Y. Ravindranath,et al.  Periodic transfusions for sickle cell anemia and CNS infarction. , 1979, American journal of diseases of children.

[11]  C. Pegelow,et al.  The natural history of stroke in sickle cell disease. , 1978, The American journal of medicine.

[12]  M. Reivich,et al.  Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. , 1976, The Journal of pediatrics.

[13]  Scott T. Miller,et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.

[14]  C. Pratt,et al.  St. Jude Children's Research Hospital. , 1997, Pediatric hematology and oncology.

[15]  Scott T. Miller,et al.  Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. , 1992, The Journal of pediatrics.

[16]  M. Reivich,et al.  Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. , 1984, Blood.

[17]  J. Lusher,et al.  A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction , 1976, American journal of hematology.